Kane Biotech
Winnipeg
About Kane Biotech
Kane Biotech Inc., a biotechnology company, engages in the research and development of products to prevent and disperse biofilms in medical and industrial applications. Its products include ALEDEX, an antimicrobial/antibiofilm composition comprising protamine sulfate and chlorhexidine, with applications in anti-infective medical device coatings, animal care and dairy, and food processing industries; DispersinB, an antibiofilm enzyme that inhibits, as well as disperses microbial biofilms, with applications in wound care, medical devices, oral care, and animal healthcare; and a toothpaste and mouthwash additive based on competence stimulating peptide technology for preventing and dispersing dental plaque biofilms. The company was founded in 2001 and is headquartered in Winnipeg, Canada.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $31.6M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jun 2025)
- Ticker: cve:KNE
- Website: kanebiotech.com
- Phone: +1 2044531314
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/kane-biotech-66762 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.